CPI-613 receives FDA orphan drug designation for soft tissue sarcoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CPI-613 (devimistat) received Orphan Drug designation from FDA for the treatment of soft tissue sarcoma.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login